Al-Sibai M B, Harder E J, Faskin R W, Johnson G W, Padmos M A
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Cancer. 1987 Oct 15;60(8):1891-5. doi: 10.1002/1097-0142(19871015)60:8<1891::aid-cncr2820600836>3.0.co;2-z.
Over a 3.5 year period from August 1982 to December 1985, 200 Hickman catheters (Evermed, Medina, WA) were inserted into patients at the King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh, Saudi Arabia. One hundred sixty catheters were placed in patients with malignant disease, many of whom were immunosuppressed at the time of catheter insertion. Seventy of 160 (44%) patients received prophylactic antibiotics and 90 (56%) did not. The mean age of each group was 23 years (range, 2 to 70 years), and the patients in each group were statistically similar in sex, underlying disease, and routine preoperative hematologic and biochemical evaluation. Exit-site wound infections occurred in 50 of 90 (55.5%) patients who did not receive prophylaxis and in 12 of 70 (17%) patients who received prophylaxis (P less than 0.0001). There was no statistically significant difference in the incidence of tunnel and incision site infections. The mean duration of antibiotic prophylaxis was 2.9 days (SD, 1.2 days). Organisms cultured from catheter associated infections, included Staphylococcus epidermidis 36, S. aureus 30, Klebsiella pneumoniae 1, Pseudomonas aeruginosa 3, Escherichia coli 1, and diphtheroids non-CDC-JK 3. Vancomycin was used as antibiotic prophylaxis in 64 patients, Kefzol (Eli Lilly, Indianapolis, IN) in one, oxacillin in three, nafcillin in one, and Septra (Burroughs Wellcome, Research Triangle Park, NC) in one. The data indicate that the use of intravenous antibiotic prophylaxis significantly reduces exit site infection and may reduce both tunnel and incision site infection. Prophylactic antibiotic coverage should be provided to patients during insertion of long-term indwelling right atrial catheters.
在1982年8月至1985年12月的3.5年期间,200根希克曼导管(Evermed公司,华盛顿州麦地那)被插入沙特阿拉伯利雅得费萨尔国王专科医院和研究中心(KFSHRC)的患者体内。160根导管被放置于患有恶性疾病的患者中,其中许多患者在导管插入时处于免疫抑制状态。160名患者中有70名(44%)接受了预防性抗生素治疗,90名(56%)未接受。每组患者的平均年龄为23岁(范围为2至70岁),且每组患者在性别、基础疾病以及术前常规血液学和生化检查方面在统计学上相似。未接受预防治疗的90名患者中有50名(55.5%)发生了出口部位伤口感染,接受预防治疗的70名患者中有12名(17%)发生了出口部位伤口感染(P<0.0001)。隧道和切口部位感染的发生率在统计学上无显著差异。抗生素预防治疗的平均持续时间为2.9天(标准差为1.2天)。从导管相关感染中培养出的微生物包括表皮葡萄球菌36株、金黄色葡萄球菌30株、肺炎克雷伯菌1株、铜绿假单胞菌3株、大肠杆菌1株以及非CDC-JK类棒状杆菌3株。64名患者使用万古霉素作为抗生素预防用药,1名患者使用头孢唑林(礼来公司,印第安纳波利斯,印第安纳州),3名患者使用苯唑西林,1名患者使用萘夫西林,1名患者使用复方新诺明(百时美施贵宝公司,北卡罗来纳州研究三角园)。数据表明,静脉使用抗生素预防可显著降低出口部位感染,并且可能降低隧道和切口部位感染。在插入长期留置的右心房导管期间,应给予患者预防性抗生素覆盖。